Cargando…
Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer
Breast cancer is a prevalent malignant cancer worldwide, and a lack of defined biomarkers for early prognostication contributes to its high associated mortality rate, especially in human epidermal growth factor receptor 2 (HER-2)-positive breast cancer. In the present study, HER-2 mRNA levels in pat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096115/ https://www.ncbi.nlm.nih.gov/pubmed/30127983 http://dx.doi.org/10.3892/ol.2018.9091 |
_version_ | 1783348047488483328 |
---|---|
author | Wu, Yanlin Meng, Qiping Yang, Zhixue Shi, Lili Hu, Rongkuan Zhang, Peizhuo Wei, Jinrong Ren, Jie Leng, Bingjing Xu, Dong Jiang, Guo-Qin |
author_facet | Wu, Yanlin Meng, Qiping Yang, Zhixue Shi, Lili Hu, Rongkuan Zhang, Peizhuo Wei, Jinrong Ren, Jie Leng, Bingjing Xu, Dong Jiang, Guo-Qin |
author_sort | Wu, Yanlin |
collection | PubMed |
description | Breast cancer is a prevalent malignant cancer worldwide, and a lack of defined biomarkers for early prognostication contributes to its high associated mortality rate, especially in human epidermal growth factor receptor 2 (HER-2)-positive breast cancer. In the present study, HER-2 mRNA levels in patients were detected prior to surgery and during neoadjuvant chemotherapy to explore its potential diagnostic and prognostic value. Blood samples were collected from 70 patients with breast cancer, including 50 HER-2-negative and 20 HER-2-positive patients, prior to and following surgery (postoperative, n=13; neoadjuvant chemotherapy, n=5); the control group included 35 samples from healthy individuals. The relative mRNA level of HER-2 in blood was determined by one-step reverse transcription-quantitative polymerase chain reaction. HER-2 expression curves of measurements taken during neoadjuvant chemotherapy were compared with the tumor size. A significant difference in the blood HER-2 mRNA level was observed between healthy women and patients with breast cancer (P<0.0001). A cutoff value of 1.512 was established for the circulating HER-2 level in healthy subjects based on the upper 95% confidence interval value of samples from the control group. The level of HER-2 mRNA in blood was associated with the HER-2 status, Ki-67 expression, and lymphovascular invasion in primary tumor tissue samples; however, there was no association with the lymph node status, tumor stage, tumor grade, tumor size, patient age, estrogen or progesterone receptor status of the primary tumor. HER-2 mRNA levels were associated with the response rate, as determined by primary tumor size, in patients who received neoadjuvant chemotherapy. In conclusion, baseline and early changes in peripheral blood HER-2 mRNA indicated that HER-2 mRNA may be a potential diagnostic biomarker for breast cancer and a prognostic marker for predicting the efficacy of neoadjuvant therapy. |
format | Online Article Text |
id | pubmed-6096115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-60961152018-08-20 Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer Wu, Yanlin Meng, Qiping Yang, Zhixue Shi, Lili Hu, Rongkuan Zhang, Peizhuo Wei, Jinrong Ren, Jie Leng, Bingjing Xu, Dong Jiang, Guo-Qin Oncol Lett Articles Breast cancer is a prevalent malignant cancer worldwide, and a lack of defined biomarkers for early prognostication contributes to its high associated mortality rate, especially in human epidermal growth factor receptor 2 (HER-2)-positive breast cancer. In the present study, HER-2 mRNA levels in patients were detected prior to surgery and during neoadjuvant chemotherapy to explore its potential diagnostic and prognostic value. Blood samples were collected from 70 patients with breast cancer, including 50 HER-2-negative and 20 HER-2-positive patients, prior to and following surgery (postoperative, n=13; neoadjuvant chemotherapy, n=5); the control group included 35 samples from healthy individuals. The relative mRNA level of HER-2 in blood was determined by one-step reverse transcription-quantitative polymerase chain reaction. HER-2 expression curves of measurements taken during neoadjuvant chemotherapy were compared with the tumor size. A significant difference in the blood HER-2 mRNA level was observed between healthy women and patients with breast cancer (P<0.0001). A cutoff value of 1.512 was established for the circulating HER-2 level in healthy subjects based on the upper 95% confidence interval value of samples from the control group. The level of HER-2 mRNA in blood was associated with the HER-2 status, Ki-67 expression, and lymphovascular invasion in primary tumor tissue samples; however, there was no association with the lymph node status, tumor stage, tumor grade, tumor size, patient age, estrogen or progesterone receptor status of the primary tumor. HER-2 mRNA levels were associated with the response rate, as determined by primary tumor size, in patients who received neoadjuvant chemotherapy. In conclusion, baseline and early changes in peripheral blood HER-2 mRNA indicated that HER-2 mRNA may be a potential diagnostic biomarker for breast cancer and a prognostic marker for predicting the efficacy of neoadjuvant therapy. D.A. Spandidos 2018-09 2018-07-05 /pmc/articles/PMC6096115/ /pubmed/30127983 http://dx.doi.org/10.3892/ol.2018.9091 Text en Copyright: © Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Wu, Yanlin Meng, Qiping Yang, Zhixue Shi, Lili Hu, Rongkuan Zhang, Peizhuo Wei, Jinrong Ren, Jie Leng, Bingjing Xu, Dong Jiang, Guo-Qin Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer |
title | Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer |
title_full | Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer |
title_fullStr | Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer |
title_full_unstemmed | Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer |
title_short | Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer |
title_sort | circulating her-2 mrna in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096115/ https://www.ncbi.nlm.nih.gov/pubmed/30127983 http://dx.doi.org/10.3892/ol.2018.9091 |
work_keys_str_mv | AT wuyanlin circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT mengqiping circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT yangzhixue circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT shilili circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT hurongkuan circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT zhangpeizhuo circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT weijinrong circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT renjie circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT lengbingjing circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT xudong circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer AT jiangguoqin circulatingher2mrnaintheperipheralbloodasapotentialdiagnosticandprognosticbiomarkerinfemaleswithbreastcancer |